

### **SGLT-2 inhibitor listing,**

Empagliflozin (Jardiance) or in combination with Metformin (Jardiamet)

#### **► SA2014 Special Authority for Subsidy**

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

1 Patient has type 2 diabetes; and

2 Any of the following:

2.1 Patient is Maori or any Pacific ethnicity; or

2.2 Patient has pre-existing cardiovascular disease or risk equivalent\*;

or

2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated

cardiovascular risk assessment calculator; or

2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during

childhood or as a young adult; or

2.5 Patient has diabetic kidney disease\*\*; and

3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one bloodglucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months; and

4 Treatment will not be used in combination with a funded GLP-1 agonist

Note: Criteria 2.1 – 2.5 describe patients at high risk of cardiovascular or renal complications of diabetes

\* Defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.

\*\* Defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m<sup>2</sup> in the presence of diabetes, without alternative cause.